Welcome to our dedicated page for Alaunos Therapeutics news (Ticker: TCRT), a resource for investors and traders seeking the latest updates and insights on Alaunos Therapeutics stock.
Alaunos Therapeutics, Inc. (TCRT) reports developments as an early-stage biotechnology company focused on orally administered small-molecule therapeutics for obesity and related metabolic disorders. Recent updates center on ALN1003, a non-hormonal, non-incretin oral candidate evaluated in preclinical diet-induced obesity models, including body-weight, liver and metabolic biomarker findings.
Company news also reflects Alaunos's transition from earlier TCR-T cell therapy programs for solid tumors, including the TCR-T Library trial, the Sleeping Beauty cell engineering platform and the hunTR discovery platform. Recurring corporate updates include operating results, research spending, capital-structure actions, Nasdaq listing compliance and governance changes.
Summary not available.
Summary not available.
Alaunos Therapeutics, Inc. (TCRT), a leader in T-cell receptor (TCR) cell therapy, announced a poster presentation for its lead Sleeping Beauty TCR-T cell therapy program at the 2023 ASCO Annual Meeting from June 2-6, 2023, in Chicago. The TCR-T Library Phase 1/2 trial is an open-label, dose-escalation study conducted at MD Anderson Cancer Center, focusing on patients with solid tumors, including non-small cell lung and colorectal cancers, who have specific targeted driver mutations. The poster will detail the safety and efficacy of TCR-T cells targeting shared KRAS and TP53 mutations. The presentation is scheduled for June 3, 2023, showcasing Alaunos' advancements in TCR therapy for cancer treatment.
Alaunos Therapeutics (Nasdaq: TCRT) announced the appointment of Robert J. Hofmeister, PhD, as Chief Scientific Officer of the Board of Directors, effective immediately. Hofmeister replaces Chris Bowden, MD. With over 25 years of expertise in T-cell therapy, Hofmeister previously led scientific teams at TCR2 Therapeutics and played a crucial role in developing their TRuC®-T cell platform. Alaunos aims to advance its TCR-T Library Phase 1/2 trial targeting solid tumors. The company benefits from its proprietary Sleeping Beauty cell engineering platform and industry-leading library of TCRs. The ongoing collaboration with the National Cancer Institute supports its research and development efforts.
Alaunos Therapeutics (Nasdaq: TCRT), a prominent T-cell receptor cell therapy company, announced its participation in two upcoming investor conferences. The first is Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, featuring fireside chats and one-on-one meetings. The second is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, which will include a company presentation and one-on-one meetings. A live webcast of the Needham presentation will be available on Alaunos' website for 90 days post-event. Alaunos is advancing TCR therapies for solid tumors and collaborates with the National Cancer Institute.
Alaunos Therapeutics (TCRT) announced transformative advancements in TCR-T cell therapy for solid tumors, showcasing promising clinical results. The company successfully enrolled patients in its TCR-T Library Phase 1/2 trial, with expectations to report interim data by mid-2023. Its TCR library has doubled, integrating new TCRs that enhance market reach. Manufacturing efficiency has improved, decreasing processing times by 13%. Financially, Alaunos reported a net loss of $9.2 million for Q4 2022, down from $11.8 million year-over-year. With $53 million in cash reserves, the company anticipates sufficient funding into Q4 2023.
Alaunos Therapeutics (TCRT) announced it will disclose its financial results for Q4 and full year 2022 on March 7, 2023, before U.S. market opening. A conference call is scheduled for 8:30 a.m. ET to discuss results and offer corporate updates. The company focuses on T-cell receptor (TCR) cell therapy aimed at solid tumors, with ongoing Phase 1/2 trials targeting six types of cancer. Alaunos utilizes proprietary platforms for TCR development and collaborates with the National Cancer Institute to advance TCR therapy.
Alaunos Therapeutics (TCRT) announces key milestones for 2023, including the addition of two new TCRs, doubling the addressable market for its TCR-T library. The company aims to enhance patient enrollment in its Phase 1/2 trial focusing on solid tumors. Manufacturing processes are being optimized for scalability, with a shift to cryopreserved products expected to reduce processing time. The mbIL-15 program is also advancing towards an IND filing in the latter half of 2023. As of Q4 2022, Alaunos reported cash and equivalents of approximately $39.1 million, projected to fund operations into Q4 2023.
Alaunos Therapeutics, Inc. (TCRT) announced a public offering of approximately 24.23 million shares at a gross proceeds of $15.7 million. The offering is set to close around December 1, 2022, subject to standard conditions. The funds will be used for the development of its product candidates and general corporate purposes. The underwriter, Cantor Fitzgerald & Co., has a 30-day option to purchase additional shares. A registration statement related to the offering has been filed with the SEC.
Alaunos Therapeutics, Inc. (TCRT) has announced an underwritten public offering of its common stock, with a 30-day option for the underwriter to purchase an additional 15% of shares. The proceeds will be used to support product development, working capital, and general corporate purposes. Cantor Fitzgerald & Co. is the sole book-running manager. The offering is contingent upon market conditions and may not proceed as planned. The registration statement for this offering was declared effective on September 7, 2022, with relevant documents available through the SEC.